A large retrospective cohort study published in BMC Cancer demonstrates a U-shaped association between serum lactate dehydrogenase (LDH) levels and all-cause mortality in cancer patients. Both abnormally low and high LDH concentrations predict increased mortality risk, suggesting its utility as a prognostic biomarker. This finding offers clinicians a nuanced metric for risk stratification and monitoring therapeutic responses in oncology care.